Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant
NCT02723435 · Stanford University · PHASE2 · withdrawn · last registry update 2018-05-04 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Logistical and administrative issues” | Open Targets' class: business administrative | Registry record, Stanford University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FLT3 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-02-20Results posted on the registry: Astellas Pharma Global Development, Inc., Gilteritinib + Voriconazole (NCT02014558)
- 2017-12-20Phase 3 first posted: Novartis Pharmaceuticals, Midostaurin + Cytarabine (NCT03379727)
- 2017-08-23Phase 3 first posted: Arog Pharmaceuticals, Inc., Crenolanib + Midostaurin (NCT03258931)
- 2017-06-09Phase 3 first posted: Astellas Pharma Inc, Gilteritinib + Cytarabine (NCT03182244)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision